Search the Newsreel

Canaccord raises Abbvie stock price target to $290 on Q2 beat

Canaccord Genuity increased its price target for Abbvie Inc. (NYSE:ABBV) to $290 from $282, maintaining a Buy rating, following the company's strong second-quarter performance. Abbvie exceeded revenue and earnings expectations, particularly in its Immunology and Neuroscience franchises, leading to a raised 2026 revenue guidance. …

AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter

Morningstar is maintaining its $200 fair value estimate for wide-moat AbbVie following a strong second quarter, which saw 10.2% top-line growth and 22.9% adjusted diluted EPS growth. The company's immunology portfolio, particularly Skyrizi and Rinvoq, continues to drive strong double-digit growth, despite increasing competition. …

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Inc. ABBV paired strong product momentum with a more complex 2026 outlook. Management raised revenue expectations, while the planned Apogee Therapeutics acquisition pushed adjusted earnings guidance modestly lower. The call focused on Skyrizi, Rinvoq and neuroscience growth, the case for Apogee and a …

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (ABBV) has successfully diversified its business beyond its previous dependence on Humira, with strong Q2 revenue and earnings growth driven by its Immunology and Neurosciences segments. Analysts maintain a "Moderate Buy" rating, anticipating the stock could reach $300 within 12 months, despite a …

AbbVie (ABBV) Stock Faces A Pivotal Growth Handoff After Guidance Lift

AbbVie Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.

AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

Why AbbVie Stock Slumped Today

AbbVie's stock fell by nearly 3% after its second-quarter earnings report, despite strong revenue growth, because its adjusted profitability of $3.65 per share missed analyst estimates of $3.71. Additionally, the company slightly cut its 2026 profitability outlook due to its acquisition of Apogee Therapeutics, …

AbbVie's Skyrizi and Rinvoq Launches Support Lengthy Patent Protection and a Wide Moat

AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading

ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down

AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …

AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition

This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …

AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal

AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

AbbVie shares fall on earnings miss and weak guidance

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …

Las acciones de AbbVie caen tras decepcionar en resultados y guidance

AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …

AbbVie Sales Beat Estimates as Botox Shows Signs of Revival

AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …

AbbVie Aktie fällt nach verfehlten Gewinnzielen und schwacher Prognose

AbbVie Q2 revenue rises 10.2% to $16.990 billion

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Inc. (ABBV) shares declined by 2.24% to $257.41, breaking a two-day winning streak, despite an overall positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on Thursday. This report highlights AbbVie's performance …

What To Expect From AbbVie’s (ABBV) Q2 Earnings

What To Expect From AbbVie's (ABBV) Q2 Earnings Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here's what to look for. AbbVie beat analysts' revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. …

JUVÉDERM marks 20 years since FDA approval with buy-one-get-one $75 cards

AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …

JUVÉDERM® Day Returns to U.S. on August 19

Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …

AbbVie, Inc. CDR (CAD Hedged) Revenue Breakdown – NEO:ABBV

This article provides a revenue breakdown for AbbVie, Inc. CDR (CAD Hedged) under the ticker NEO:ABBV, sourced from TradingView. It highlights that the United States was the primary contributor to AbbVie's revenue, bringing in 65.12 billion CAD last year and 58.95 billion CAD the …

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh Revenue Breakdown – BMFBOVESPA:ABBV34 – TradingView

This article provides a revenue breakdown for AbbVie, Inc. Brazilian Depository Receipts (ABBV34) traded on the BMFBOVESPA, highlighting that the United States is the largest contributor to its revenue. The financial data indicates significant revenue in BRL during the last two years.

The Real Price of AbbVie Stock Is Cheaper Than You Think

AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven …

AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run

AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. This approval marks Rinvoq as the first systemic treatment of its kind for …

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …